JCI vs LCTX · P/E 44, rev $23.60B vs rev $2.8M
Johnson Controls International PLC (JCI) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
Johnson Controls International PLC (JCI) is a building products & equipment company listed on NYSE.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Latest reported JCI revenue for 2025-09-30 was $23.60B. Net income was $3.51B. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
Latest reported LCTX revenue for 2026-06-30 was $2.8M. Net income was -$3.3M. Revenue was up 62.0% from 2026-03-31 to 2026-06-30. LCTX currently screens at market cap $213.6M.
JCI currently screens at market cap $87.62B and trailing P/E 43.9. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the JCI and LCTX stock pages for the full models.
Not investment advice.